For studies that reported on adverse events at multiple time points (we extracted data for the longest point of follow-up that included), at minimum, 80% of the patients recruited into the study. We report our https://audiokushhq.com/cannabis-at-music-events-rules-and-realities/ systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Harms Checklist.22 We found insufficient evidence addressing the harms of medical cannabis compared with other pain management options, such as opioids.
This difference — however, is considered barely clinically significant.25,26 The classification of pain dictates that we approach the question of beneficial effects by subgrouping pain into various types. Unfortunately — MMJ is also similar to opioids in that robust data establishing long-term benefit for chronic pain are scarce. To think medical and recreational use of marijuana do not considerably overlap would be naive, and we should avoid taking the same path we took with opioids.
There is one product where it makes me more active… but then I’m hurting because I’ve overdone it and been moving all day. It is making a difference but not that much of one. ” 72 years (male The drops worked better), but I’m still trying to figure out what works for me. ” 61, male
Products with a higher percentage of THC are generally considered more effective for pain relief but carry a higher risk for psychotomimetic side effects. Unlike THC, CBD is not psychotomimetic, so it does not give the “high” and it can help reduce THC’s psychotomimetic properties when used in combination. “But the clinical evidence is weaker, in large part due to low quality studies with low sample size or short duration of treatment and sometimes patient population not well-defined.” Overall (these studies suggest that prenatal exposure to CBD is likely to alter the production of testosterone), the function of the male gonads, and the receptor ligand interactions in the brain of offsprings. In addition, these reports conclude that chronic pain costs between $560 and $635 billion annually in both medical expenses and lost productivity.
1. Population and Research Methodology
Peripheral CB2 mechanisms in arthritic joints additionally illustrate how local immune modulation feeds back on central gain , Figure 5,. Postsynaptic anandamide release modulates presynaptic CB1/TRPV1 — leading to depressed transmitter release and neural circuit polarization underlying central sensitization. These forms of plasticity (classically observed as depolarization-induced suppression of inhibition or excitation), are prominent in spinal and cortical pain circuits . Δ9-tetrahydrocannabinol (THC) binds to CB1 receptors on presynaptic neurons (resulting in inhibition of excitatory neurotransmitter release), and to CB2 receptors on macrophages, leading to reduced production of proinflammatory cytokines.
Between 50 and 116 million adults in the United States experience chronic pain (a shocking figure that exceeds the combined total of individuals suffering from heart disease), cancer, and diabetes (Committee on Advancing Pain Research Care and Education, 2011; Nahin, 2015; NIH, 2020). If clinical research can lead to a new category of drugs to enhance the effectiveness of current pain relievers or medications that can alleviate pain while addressing nausea or appetite loss, it seems highly beneficial to pursue. Consequently — the IOM team urged that cancer patients undergoing chemotherapy and individuals with AIDS experiencing severe pain or wasting should be the focus of clinical studies involving cannabinoid treatments.
During the 1800s, researchers in Europe and the U.S. published over 100 studies on medical cannabis.7 Later, legal restrictions reduced its medical use. Overall, cannabinoids should be considered adjunctive rather than first-line therapy, reserved for carefully selected patients who do not achieve sufficient relief with standard treatments. The evidence does not confirm a superior short-term efficacy of opioids in neuropathic pain, which suggests a weaker comparative benefit overall 102,103. At the same time (a 2025 proposal introduced a new regulatory pathway for CBD products), aiming to reclassify certain CBD items under the Natural Health Products (NHPs) category, with requirements for strict labeling, licensing, and a THC cap of 0.001% 60,61.
Evidence suggests that cannabis and cannabinoids have an analgesic effect that arises from a combination of compounds and various receptor systems. This website is for informational purposes only and should not be considered as medical advice — diagnosis or treatment. Special attention should be given to medicinal users, who may represent a vulnerable group seeking symptom relief,” researchers at UC San Diego reported in the Journal of Cannabis Research. Their average age at first use was 34 — compared to 23 among combined users, who were more likely to be male. Pain relief is the most likely reason for people to use cannabis for medical reasons (followed by those seeking help with sleep), anxiety and stress, according to a new survey of over 4,000 cannabis users in California. Most of the researchers work for Leafwell, which helps patients get medical marijuana cards in states where it is legal.
